TY  - GEN
AU  - Maurer,M J
AU  - Habermann,T M
TI  - Reply to the letter to the editor 'Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting' by van der Galiën et al
SN  - 1569-8041
PY  - 2019///1018
KW  - Humans
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - Progression-Free Survival
KW  - Randomized Controlled Trials as Topic
KW  - Rituximab
N1  - Publication Type: Letter; Research Support, Non-U.S. Gov't; Comment
UR  - https://doi.org/10.1093/annonc/mdy492
ER  -